 By David Bautz, PhD NASDAQ:BCLI READ THE FULL OGEN RESEARCH REPORT Business Update Developing Vaccine Against SARS-CoV-2 On May 4, 2020, Oragenics, Inc. OGEN announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 the virus that causes COVID-19 that is licensed from the National Institute of Allergy and Infectious Diseases 